MedTrace Logo

Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2

NCT04887948 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 570

Last updated 2022-12-14

Study results available
· View outcomes & findings →

Summary

Study of the safety and immunogenicity of 20vPnC and a booster dose of BNT162b2 administered at the same visit or each vaccine given alone

Conditions

Interventions

BIOLOGICAL

20-valent pneumococcal conjugate vaccine (20vPnC)

20-valent pneumococcal conjugate vaccine (20vPnC)

BIOLOGICAL

BNT162b2

RNA-based SARS-CoV-2 vaccine (BNT162b2)

OTHER

Saline

Normal saline for injection

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-20
Primary Completion
2021-12-08
Completion
2021-12-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04887948 on ClinicalTrials.gov